These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 3413719)

  • 1. Is there an optimal therapeutical range for low molecular weight heparin? An experimental study.
    Doutremepuich C; Gestreau JL; Doutremepuich F; Lalanne MC; Kuttler MC; Toulemonde F
    Thromb Res; 1988 May; 50(4):575-81. PubMed ID: 3413719
    [No Abstract]   [Full Text] [Related]  

  • 2. Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction.
    Doutremepuich C; Gestreau JL; Maury MO; Quilichini R; Boisseau MR; Toulemonde F; Vairel E
    Haemostasis; 1983; 13(2):109-12. PubMed ID: 6873751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of heparin and a low molecular weight heparin fraction of the leukocytes in an experimental venous thrombosis model.
    Doutremepuich C; Toulemonde F; de Seze O; Pereira F; Anne MC; Doutremepuich F
    J Leukoc Biol; 1987 Dec; 42(6):628-31. PubMed ID: 2824648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study on the effects of a low molecular weight heparin (CY 216) and standard heparin in low dosage on experimental venous thrombosis.
    Doutremepuich C; Bousquet F; Gestreau GL; Toulemonde F; Bayrou B
    Haemostasis; 1987; 17(4):201-5. PubMed ID: 3623263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Low molecular weight heparin in venous thromboembolism. Mechanism of action, therapy and prophylaxis].
    Stammler F; Diehm C
    Dtsch Med Wochenschr; 1998 May; 123(19):604-11. PubMed ID: 9618643
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis.
    Mungall D; Raskob G; Coleman R; Rosenbloom D; Ludden T; Hull R
    J Clin Pharmacol; 1989 Oct; 29(10):896-900. PubMed ID: 2592581
    [No Abstract]   [Full Text] [Related]  

  • 7. Laboratory control of heparin and heparin fragment treatment: an experimental study.
    Doutremepuich C; Lalanne MC; Guyot M; Doutremepuich F; De Sèze O; Toulemonde F
    Semin Thromb Hemost; 1989 Oct; 15(4):373-7. PubMed ID: 2554497
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term intraperitoneal application of low molecular weight heparin in a continuous ambulatory peritoneal dialysis patient with deep vein thrombosis.
    Schrader J; Tönnis HJ; Scheler F
    Nephron; 1986; 42(1):83-4. PubMed ID: 3941753
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of the effects of sodium pentosanpolysulfate and unfractionated heparin on venous thrombosis; an experimental study in rats.
    Kiesel J; Harbauer G; Wenzel E; Pindur G; Bohnerth S
    Thromb Res; 1991 Nov; 64(3):301-8. PubMed ID: 1725226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thrombolytic action of heparin and a low molecular weight fraction].
    Bousquet F; Doutremepuich C; Gestreau JL; Masse A; Toulemonde F; Vairel EG
    Therapie; 1985; 40(1):13-6. PubMed ID: 4002178
    [No Abstract]   [Full Text] [Related]  

  • 11. Antithrombotic effects of heparin and related agents.
    Hladovec J; Kornalík F
    Cor Vasa; 1991; 33(1):68-74. PubMed ID: 1655354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modifications of biological activities of heparin and fraxiparine induced by the size and the age of a thrombus. Experimental study.
    Doutremepuich C; Llido S; Lalanne MC; Doutremepuich F
    Thromb Res; 1990 Aug; 59(3):439-47. PubMed ID: 2237821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of venous thromboembolism: unfractionated heparin or low molecular weight heparins?
    Agnelli G
    Haematologica; 1995; 80(2 Suppl):78-83. PubMed ID: 7628776
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative study on heparin and a synthetic thrombin inhibitor no. 805 (MD-805*) in experimental antithrombin III-deficient animals.
    Kumada T; Abiko Y
    Thromb Res; 1981 Nov; 24(4):285-98. PubMed ID: 6977887
    [No Abstract]   [Full Text] [Related]  

  • 15. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.
    Holm HA; Ly B; Handeland GF; Abildgaard U; Arnesen KE; Gottschalk P; Høeg V; Aandahl M; Haugen K; Laerum F
    Haemostasis; 1986; 16 Suppl 2():30-7. PubMed ID: 3527886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].
    MMW Fortschr Med; 2003 Jun; 145(24):56. PubMed ID: 12866309
    [No Abstract]   [Full Text] [Related]  

  • 17. Results of low-dose heparin prophylaxis of venous thrombosis considering plasma heparin and anti-thrombin III concentration.
    Tilsner V; Müller U; Reuter H; Raedler A
    Thromb Res; 1980 Feb 1-15; 17(3-4):519-25. PubMed ID: 7368173
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects and clinical significance of heparin and phenindione on a standard experimental femoral venous thrombus.
    Johnson DC; Reeve TS
    Aust N Z J Surg; 1969 Nov; 39(2):209-16. PubMed ID: 5264528
    [No Abstract]   [Full Text] [Related]  

  • 19. [Infusion thrombophlebitis and local anticoagulation therapy with heparin].
    Thayssen P
    Ugeskr Laeger; 1974 Jul; 136(30):1679-82. PubMed ID: 4610936
    [No Abstract]   [Full Text] [Related]  

  • 20. Enteral administration of heparin.
    Kidron M; Eldor A; Lichtenberg D; Touitou E; Ziv E; Bar-On H
    Thromb Res; 1979; 16(5-6):833-5. PubMed ID: 524324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.